|
FI903489A7
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US8076459B2
(en)
|
2003-10-16 |
2011-12-13 |
Micromet Ag |
Multispecfic deimmunized CD3-binders
|
|
SG188175A1
(en)
|
2004-06-03 |
2013-03-28 |
Novimmune Sa |
Anti-cd3 antibodies and methods of use thereof
|
|
CA2606081C
(en)
*
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
US8236308B2
(en)
|
2005-10-11 |
2012-08-07 |
Micromet Ag |
Composition comprising cross-species-specific antibodies and uses thereof
|
|
WO2008119565A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific binding domain
|
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
RU2012115480A
(ru)
*
|
2009-09-18 |
2013-10-27 |
Микромет Аг |
РЕЖИМ ДОЗИРОВАНИЯ ПРИ ВВЕДЕНИИ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА EpCAMxCD3
|
|
CN103533943B
(zh)
*
|
2010-11-10 |
2018-02-13 |
安进研发（慕尼黑）股份有限公司 |
由cd3特异性结合结构域导致的不良作用的预防
|
|
WO2012162067A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
IN2014MN02293A
(enExample)
|
2012-04-20 |
2015-08-07 |
Emergent Product Dev Seattle |
|
|
EP2892924B1
(en)
|
2012-06-14 |
2020-11-25 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
WO2013188693A1
(en)
|
2012-06-15 |
2013-12-19 |
Imaginab, Inc. |
Antigen binding constructs to cd3
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
MX2015003616A
(es)
*
|
2012-10-08 |
2015-06-05 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
CN110437337B
(zh)
*
|
2013-02-26 |
2024-07-30 |
罗切格利卡特公司 |
双特异性t细胞活化性抗原结合分子
|
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
HK1217023A1
(zh)
|
2013-05-28 |
2016-12-16 |
Numab Innovation Ag |
新型抗体
|
|
KR102813816B1
(ko)
|
2013-07-05 |
2025-05-29 |
젠맵 에이/에스 |
인간화 또는 키메라 cd3 항체
|
|
AP2016009222A0
(en)
|
2013-11-04 |
2016-05-31 |
Glenmark Pharmaceuticals Sa |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
|
HUE050159T2
(hu)
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-CD3 antitestek és alkalmazási eljárások
|
|
US20170073415A1
(en)
|
2014-05-12 |
2017-03-16 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
CN106459201A
(zh)
|
2014-05-28 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
结合人和食蟹猴CD3ε的抗体
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
AR103488A1
(es)
|
2015-01-23 |
2017-05-10 |
Sanofi Sa |
Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
|
|
HUE057285T2
(hu)
|
2015-04-13 |
2022-04-28 |
Pfizer |
Terápiás ellenanyagok és alkalmazásaik
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
WO2017010874A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
|
FI3322727T3
(fi)
|
2015-07-15 |
2026-03-17 |
Genmab As |
Humanisoituja tai kimeerisiä CD3-vasta-aineita
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
MY195059A
(en)
|
2015-09-23 |
2023-01-05 |
Regeneron Pharma |
Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
|
|
JP7044700B2
(ja)
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
|
|
BR112018011029A2
(pt)
*
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
HRP20251020T1
(hr)
|
2016-05-20 |
2025-10-24 |
Harpoon Therapeutics, Inc. |
Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
|
|
IL299221A
(en)
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
Cd3 binding antibodies
|